Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2应助小丑之花采纳,获得30
刚刚
科研通AI6.4应助小丑之花采纳,获得30
刚刚
清秀豆芽发布了新的文献求助10
刚刚
清秀豆芽发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
1秒前
清秀豆芽发布了新的文献求助10
1秒前
tonghau895完成签到 ,获得积分10
1秒前
1799完成签到,获得积分10
1秒前
清秀豆芽发布了新的文献求助10
1秒前
1秒前
清秀豆芽发布了新的文献求助10
2秒前
清秀豆芽发布了新的文献求助10
2秒前
原yuan完成签到,获得积分10
2秒前
2秒前
清秀豆芽发布了新的文献求助10
2秒前
清秀豆芽发布了新的文献求助10
2秒前
清秀豆芽发布了新的文献求助10
3秒前
清秀豆芽发布了新的文献求助10
3秒前
清秀豆芽发布了新的文献求助10
3秒前
清秀豆芽发布了新的文献求助10
3秒前
清秀豆芽发布了新的文献求助10
3秒前
清秀豆芽发布了新的文献求助10
3秒前
清秀豆芽发布了新的文献求助10
3秒前
jin完成签到,获得积分10
3秒前
霸气梦菲发布了新的文献求助10
4秒前
勤恳祥发布了新的文献求助10
4秒前
星河万里完成签到,获得积分10
4秒前
陆阳阳发布了新的文献求助10
5秒前
勤恳的凝云完成签到,获得积分10
5秒前
6秒前
6秒前
轻松博超完成签到,获得积分10
6秒前
6秒前
朴素寄文发布了新的文献求助10
6秒前
智胜东方朔完成签到,获得积分10
6秒前
7秒前
汪ke发布了新的文献求助10
7秒前
高分求助中
Cronologia da história de Macau 5000
Matrix Methods in Data Mining and Pattern Recognition 510
C语言程序设计(微课版) 500
Interactions of Vowel Quality and Prosody in East Slavic 500
Vander's Renal Physiology第10版 500
Forensic Science An Introduction to Scientific and Investigative Techniques 6th Edition 400
Reaction of 3-Methylenedihydro-(3H)furan-2-one with Diazoalkanes. Syntheses and Crystal Structures of Spiranic Cyclopropyl Compounds 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7094893
求助须知:如何正确求助?哪些是违规求助? 8751541
关于积分的说明 18510238
捐赠科研通 6647845
什么是DOI,文献DOI怎么找? 3137431
关于科研通互助平台的介绍 2245449
邀请新用户注册赠送积分活动 2112212